Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients

NCT01202591 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

127

Enrollment

INDUSTRY

Sponsor class

Conditions

FGFR Inhibition, Pharmacokinetics, Biomarkers
ER+ Breast Cancer

Interventions

DRUG: AZD4547
DRUG: Exemestane
DRUG: Placebo
DRUG: Fulvestrant

Sponsor

AstraZeneca